Shilpa Medicare gets marketing authorization from Portugal for Tadalafil Orodispersible Films

10 Jan 2025 Evaluate

Shilpa Medicare has received Marketing Authorization from Portugal, Europe, for Tadalafil Orodispersible Films, 20 mg. The total Europe market for oral Tadalafil formulations is estimated at about $400 million. Shilpa Medicare becomes the first company in the World to receive approval for this product as a convenient, patient friendly oral mouth dissolving/dispersing Film formulation. This approval is a hybrid application and Shilpa’s product is bioequivalent to the reference product. Tadalafil is indicated for the treatment of erectile dysfunction (sometimes called impotence) in adult males. 

This approval has come from the company’s finished dosage form manufacturing facility, Unit VI, located at Dabaspet, Bengaluru, Karnataka. The facility is currently approved by MHRA UK and this is the second approval for a prescription oral mouth dissolving film product in the European/UK regulated markets from the facility. The facility is involved in manufacturing, packaging, labelling and testing of finished dosage forms (oral dispersible/dissolving Films and Transdermal Patches).  

Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.


Shilpa Medicare Share Price

641.05 17.35 (2.78%)
05-Mar-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1581.95
Dr. Reddys Lab 1126.55
Cipla 1418.45
Lupin 2009.65
Zydus Lifesciences 887.55
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.
Please wait your portfolio is updating...